Table 1.

Bacterial strains and plasmids used in this study

Strain or plasmidRelevant genotype or phenotypeSource or reference
E. coli
  DH10BaraD139Δ(ara, leu)7697 deoR endA1 galK1 galU nupG recA1 rpsL F′-mcrAΔ(mrr-hsdRMS-mrcBC)Φ80dlacZΔM15 ΔlacX74Gibco BRL, Paris, France
  JM109endA1 gyrA96 hsdR17 Δ(lac proA) relA recA1 supE44 thi F′ (lacIqlacZΔM15proAB+ traD36)17
  In vitro-obtained rifampin-resistant JM109Rifampin resistant17
P. aeruginosa
  COL-1Carbapenem-resistant clinical isolateThis study
  MKAM 12Carbapenem-resistant clinical isolate producing IMP-1Y. Arakawa
  In vitro-obtained ciprofloxacin-resistant P. aeruginosa PU21Ciprofloxacin resistant ilv leu streptromycin resistant17
 pNOR-200045-kb natural plasmid that encodedblaVIM-2This study
 pBK-CMVNeomycin resistant kanamycin resistantStratagene, Inc. (Ozyme, Saint-Quentin-en-Yvelines, France)
 pNOR-2001Recombinant plasmid containing a 3,843-bp BamHI insert encodingblaVIM-2 into pBK-CMVThis study